Skip to main content

Table 2 Study Outline

From: Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)

Target number of patients: 408 patients


Study Design: Randomization

Aspirin group (81–100 mg/day; Group A)

Cilostazol group (100–200 mg/day; Group C)

Follow-up: 2-year prospective follow-up study


Primary endpoints:


   IMT*: Variation of right and left max IMT-CCA and mean IMT-CCA


Secondary endpoints:


   IMT*: Variation of right and left max IMT-ICA

  1. *Variation is measured by the IMT Evaluation Committee by using a diagnostic software application called IntimaScope® while the allocations are blinded.